Drug intelligence / Profile preview

CDR-505

Development stage: Preclinical
Lead developer: CDR-Life
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

CDR-505 is a bispecific T-cell engager (TCE) antibody developed by CDR-Life. It targets the KK-LC-1 peptide presented by HLA-A*01 on tumor cells and the CD3 receptor on T-cells, enabling potent and selective killing of KK-LC-1-positive cancer cells. This approach is designed to activate CD8+ T-cells specifically against tumors expressing the KK-LC-1/HLA-A*01 complex, expanding immunotherapy options for solid tumors in patient populations not addressed by other TCR-based therapeutics. The drug is currently in preclinical development for solid tumors[1][3][4][6].

Targets

KK-LC-1/HLA-A*01 (Kita-Kyushu lung cancer antigen 1 peptide in complex with HLA-A*01)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on CDR-505.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDR-505.

Explore the full profile